The Relationship Between Glycosylated Hemoglobin and Myocardial Perfusion Imaging
Article first published online: 29 JUN 2012
© 2012 Wiley Periodicals, Inc.
Volume 35, Issue 9, pages 565–569, September 2012
How to Cite
Lynn Fillipon, N. M., Kitkungvan, D., Dani, S. S. and Downey, B. C. (2012), The Relationship Between Glycosylated Hemoglobin and Myocardial Perfusion Imaging. Clin Cardiol, 35: 565–569. doi: 10.1002/clc.22028
- Issue published online: 10 SEP 2012
- Article first published online: 29 JUN 2012
- Manuscript Revised: 3 MAY 2012
- Manuscript Received: 22 OCT 2011
The relationship between long-term glucose control (measured by glycosylated hemoglobin [HgbA1C]) and myocardial perfusion imaging (MPI) abnormalities in symptomatic diabetic patients has not been studied.
We hypothesized that diabetic patients with poorly controlled HgbA1C would have more abnormal MPI compared to both patients without diabetes and diabetic patients with tighter glycemic control.
This was a retrospective evaluation of 1037 consecutive patients referred for MPI. All patients completed a 1-day MPI protocol. The electronic medical records were accessed for demographics and relevant medical history.
Diabetic patients had a higher risk of abnormal MPI (including ischemia, infarction, and mixed ischemia/infarction) compared to nondiabetic patients (relative risk [RR] = 1.77). The populations with suboptimal (HgbA1C ≥7%) and poor (HgbA1C ≥8%) glycemic control had significantly higher risk of abnormal MPI (RR = 1.78 and 2.17, respectively) compared to nondiabetic patients. Coronary angiography supported the MPI results; 66% of diabetic patients had coronary artery disease (CAD), which was higher than the 53% of patients without diabetes found to have CAD.
The importance of strict glycemic control to reduce cardiovascular complications in diabetic patients is well known. Our study shows a significantly higher risk of abnormal MPI and CAD in diabetic patients with suboptimal and poor long-term glycemic control, further emphasizing the need for aggressive risk factor modification to minimize vascular complications from DM. Clin. Cardiol. 2012 doi: 10.1002/clc.22028
The authors have no funding, financial relationships, or conflicts of interest to disclose.